Agilent Technologies Stock

$114.62

0.56% yesterday

NYSE, Aug 08, 10:00 pm CET

ISIN

US00846U1016

Symbol

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

Agilent Technologies Stock price

$114.62

+17.48 17.99% 5Y

NYSE, Closing price Fri, Aug 08 2025

+0.64 0.56%

ISIN

US00846U1016

Symbol

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$32.4b

Enterprise Value

$34.4b

Net debt

$2.0b

Cash

$1.5b

Shares outstanding

283.9m

Valuation (TTM | estimate)

P/E

27.9 | 20.0

P/S

4.9 | 4.7

EV/Sales

5.2 | 5.0

EV/FCF

28.9

P/B

5.3

Dividends

DPS

$0.94

Yield 1Y | 5Y

0.8% | 0.7%

Growth 1Y | 5Y

4.9% | 7.6%

Payout 1Y | 3Y

21.3% | 21.0%

Increased

13 Years

Financials (TTM | estimate)

Revenue

$6.6b | $6.9b

EBITDA

$1.8b | $2.1b

EBIT

$1.5b | $1.8b

Net Income

$1.2b | $1.6b

Free Cash Flow

$1.2b

Growth (TTM | estimate)

Revenue

0.6% | 6.4%

EBITDA

13.6% | 13.0%

EBIT

14.8% | 14.7%

Net Income

-6.1% | 25.3%

Free Cash Flow

-22.7%

Financial Health

Equity Ratio

49.8%

Return on Equity

21.9%

ROCE

15.2%

ROIC

13.8%

Debt/Equity

0.6

EPS

$4.1

FCF per Share

$4.2

Short interest

1.4%

Employees

18k

Rev per Employee

$360.0k

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Get Started for Free Today

Agilent Technologies Stock Analysis

Unlock Scores for Free

??

26 Analysts have issued a Agilent Technologies forecast:

14x Buy

54%

12x Hold

46%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a Agilent Technologies forecast:

Buy

54%

Hold

46%

Analyst Estimates with Stock Price Targets

Financial data from Agilent Technologies

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Apr '25		+/- %
Revenue	6,628 6,628	1% 1% 100%
- Direct Costs	3,064 3,064	6% 6% 46%
Gross Profit	3,564 3,564	6% 6% 54%
- Selling and Administrative Expenses	1,577 1,577	2% 2% 24%
- Research and Development Expense	441 441	2% 2% 7%
EBITDA	1,823 1,823	14% 14% 28%
- Depreciation and Amortization	277 277	7% 7% 4%
EBIT (Operating Income) EBIT	1,546 1,546	15% 15% 23%
Net Profit	1,166 1,166	6% 6% 18%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Agilent Technologies Stock News

Neutral

Business Wire

●

5 days ago

Agilent Expands the Dako Omnis Family with Three New Models to Meet Evolving Pathology Lab Needs

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of pathology laboratories of all sizes. These new instruments provide labs with the flexibility to tailor their staining solutions according to volume,...

Positive

Seeking Alpha

●

8 days ago

Monthly Pay Dividends, From 83 Equities, 80 Funds, And 28 Ideal 'Safer' Dogs For August

Most MoPay equities and funds offer annual dividends from a $1K investment that exceed their share price, presenting affordable but volatile opportunities. Analyst estimates suggest the top ten MoPay stocks could generate 16% to 104% total returns by August 2026, with an average gain of 30.56%. The 'dogcatcher' strategy identifies high-yield, contrarian picks, but emphasizes caution due to vola...

Positive

Reuters

●

11 days ago

Agilent Tech looks to double investments in India, eyes high-teen growth, CEO says

U.S.-based laboratory equipment maker Agilent Technologies plans to double its investments in India to expand in one of its fastest-growing markets, a top executive said.

More Agilent Technologies News

Company Profile

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Head office	United States
CEO	Padraig Mcdonnell
Employees	17,900
Founded	1999
Website	www.agilent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now